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Apocynin Exerts Dose-Dependent Cardioprotective Effects by Attenuating
Reactive Oxygen Species in Ischemia/Reperfusion
Qian Chen, Woodworth Parker C, Issachar Devine, Regina Ondrasik, Tsion Habtamu, Kyle D Bartol, Brendan Casey, Harsh Patel, William
Chau, Tarah Kuhn, Robert Barsotti and Lindon Young*
Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine, Philadelphia, USA

Abstract
Ischemia/reperfusion results in cardiac contractile dysfunction and cell death partly due to increased reactive oxygen
species and decreased endothelial-derived nitric oxide bioavailability. NADPH oxidase normally produces reactive
oxygen species to facilitate cell signalling and differentiation; however, excessive release of such species following
ischemia exacerbates cell death. Thus, administration of an NADPH oxidase inhibitor, apocynin, may preserve
cardiac function and reduce infarct size following ischemia. Apocynin dose-dependently (40 μM, 400 μM and 1
mM) attenuated leukocyte superoxide release by 87 ± 7%. Apocynin was also given to isolated perfused hearts
after ischemia, with infarct size decreasing to 39 ± 7% (40 μM), 28 ± 4% (400 μM; p < 0.01) and 29 ± 6% (1
mM; p < 0.01), versus the control’s 46 ± 2%. This decrease correlated with improved final post-reperfusion left
ventricular end-diastolic pressure, which decreased from 60 ± 5% in control hearts to 56 ± 5% (40 µM), 43 ± 4%
(400 μM; p < 0.01) and 48 ± 5% (1 mM; p < 0.05), compared to baseline. Functionally, apocynin (13.7 mg/kg,
I.V.) significantly reduced H2O2 by nearly four-fold and increased endothelial-derived nitric oxide bioavailability by
nearly four-fold during reperfusion compared to controls (p < 0.01), which was confirmed in in vivo rat hind limb
ischemia/reperfusion models. These results suggest that apocynin attenuates ischemia/reperfusion-induced cardiac
contractile dysfunction and infarct size by inhibiting reactive oxygen species release from NADPH oxidase.

Keywords: NADPH oxidase; Apocynin; Myocardial ischemia/
reperfusion; Hind limb ischemia/reperfusion; Nitric oxide; Hydrogen
peroxide; Leukocyte superoxide release

Introduction
Coronary heart disease is the leading cause of death worldwide
[1]. The most effective therapeutic intervention for reducing infarct
size associated with myocardial ischemic injury is timely and effective
reperfusion of blood flow back to the heart tissue by percutaneous
coronary intervention. However, the reperfusion of blood itself can
induce additional cardiomyocyte death that can account for up to
50% of the final infarct size [2]. Remarkably, after several decades of
preclinical and clinical studies, there is still no effective therapy to
limit reperfusion-induced tissue death and improve post-reperfused
cardiac function. Consequently, there is a great need to identify the
mechanism(s) responsible for myocardial ischemia/reperfusion injury.
Ischemia/reperfusion injury is initiated in part by endothelial
dysfunction, which occurs within 5 min of reperfusion. It is characterized
by an increase in reactive oxygen species leading to endothelial nitric
oxide synthase uncoupling, which in turn causes more reactive oxygen
species production and limited endothelial-derived Nitric Oxide
(NO) bioavailability [2-4]. The reduced NO bioavailability leads to
compromised blood flow during reperfusion and increased leukocyteendothelial interactions, which will exacerbate tissue damage. The time
course of endothelial dysfunction in myocardial ischemia/reperfusion
is similar to other vascular beds, such as hind limb ischemia/reperfusion
and splanchnic ischemia/reperfusion [5,6]. The significance of this
commonality is that compounds that attenuate endothelial dysfunction
in the heart could be applied to other vascular beds such as pulmonary,
kidney, liver, mesenteric and limb circulation. Therefore, this could
be clinically applied to prevent organ damage in various ischemia/
reperfusion injury settings, such as organ transplantation, circulatory
shock, prolonged tourniquet use and coronary bypass/balloon
angioplasty.
In order to understand endothelial dysfunction during ischemia/
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reperfusion, we established an in vivo rat hindlimb ischemia/
reperfusion injury model that directly measures reactive oxygen species
levels in blood (i.e., hydrogen peroxide [H2O2]) and NO in real-time
[4,7,8] from both femoral veins (with one limb subjected to ischemia/
reperfusion and the other serving as a sham control). H2O2 is an indirect
index of superoxide (SO) release because SO dismutase rapidly, within
seconds, converts SO to H2O2; this process is enhanced under low pH
conditions [9,10]. Our hind limb ischemia/reperfusion injury model
is appropriate to measure H2O2 and NO blood levels during ischemia/
reperfusion because the direct measurements are not feasible in the
coronary circulation of the isolated perfused rat heart model. We found
that an inverse relationship exists between blood H2O2 and NO levels
in ischemia/reperfusion . Greater production of H2O2 and reduction
of NO during reperfusion in hind limb ischemia/reperfusion closely
correlates with a greater degree of post-reperfused cardiac dysfunction
in myocardial ischemia/reperfusion [4,7,8].Therefore, quantifying
blood reactive oxygen species release and NO levels in real-time during
reperfusion is important to determine the initiating sources of reactive
oxygen species in ischemia/reperfusion and to develop potential
treatment strategies for ameliorating reperfusion injury.
Although clinical trials suggest non-selective antioxidants do not
effectively attenuate reperfusion injury, this may be due to lack of
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specifically targeting the source of oxidative stress. Four enzymatic
sources principally contribute to oxidative stress (i.e., reactive oxygen
species) during reperfusion: NADPH oxidase, xanthine oxidase,
uncoupled eNOS, and the mitochondrial electron transport chain.
NADPH oxidases comprise a family of enzymes that initiates and
recruits the other three sources as follows [11]: 1. NADPH oxidase 2
(Nox2) naturally produces SO/H2O2 upon the assembly of the cytosolic
subunits (i.e., rac, p67phox, p47phox, and p40phox) with, the membrane
subunits (i.e., p22phox and gp91phox); 2. It is expressed in many cells in the
heart, such as vascular endothelium and cardiac myocytes, and is the
principle source of SO release in leukocytes; 3. SO/H2O2 release from
activated NADPH oxidase can open mitochondrial ATP-dependent
potassium channels and/or mitochondria permeability transition pores,
which further lead to mitochondrial matrix alkalization, mitochondrial
electron transport chain uncoupling, and SO production [12]; 4.
Overproduction of SO/H2O2 will also promote the transformation
of xanthine dehydrogenase into xanthine oxidase [13,14]; 5. SO can
quench NO to form peroxynitrite anion, which in turn can promote
eNOS uncoupling via the oxidation of the essential eNOS co-factor
tetrahydrobiopterin (BH4) to dihydrobiopterin (BH2) [15]. It has
been found in vitro that the increased ratio of BH2 to BH4 facilitates
BH2 binding at the eNOS oxygenase domain, allowing eNOS to use
molecular oxygen to produce SO and, subsequently, H2O2 in blood
[16]. 6. Reactive oxygen species release during reperfusion serves as a
key initiating factor that triggers the release of a major inflammatory
cytokine, tumor necrosis factor, alpha (TNFα), within the first 15 min
of reperfusion [12,17-20] (Figure 1).
Consequently, inhibition of Nox2 may be an effective strategy to
prevent the downstream sequelae of reperfusion injury and salvage
heart tissue during myocardial infarction or organ transplantation.
Previous studies show apocynin, an alkaloid derived from Apocynum
cannabinum, is a selective Nox2 assembly inhibitor that may oxidize

the thiols in NADPH oxidase. Moreover, apocynin may be a prodrug
and thus needs to be activated by peroxidase-mediated oxidation to
diapocynin, its active oxidizing form, which is illustrated in Figure 2.
Specifically, the effects of apocynin oxidize the cysteine-196 position
of p47phox, a cytosolic component of NADPH oxidase that is activated
via phosphorylation by protein kinase C, which, in turn, inhibits the
association of the p22phox membrane subunit component of NADPH
oxidase and, therefore inhibit Nox2 assembly and subsequent SO
release, thereby decreased oxidative stress and tissue damage [21,22].
We hypothesize that administration of selective NADPH oxidase
inhibitors, such as apocynin, will dose-dependently attenuate
blood H2O2 and augment NO bioavailability in hindlimb ischemia/
reperfusion, and will decrease SO release from leukocytes and reduce
infarct size/area-at-risk in ischemia/reperfusion hearts, and thus
improving post-reperfused cardiac function.

Methods
Animals
All animal procedures were approved by the Institutional Animal
Care and Use Committee at PCOM for care and use of animals. Male
Sprague Dawley (SD) rats (275-325 g; Ace Animals, Boyertown, PA)

Measurement of SO release from rat PMNs
The SO release from Poly Morphonuclear Leukocytes (PMNs)
was measured spectrophotometrically (model 260 Gilford, Nova
Biotech; El Cajon, CA) by the reduction of ferricytochrome c as
previously described [23]. The PMNs (5 × 106) were resuspended in
450 μl PBS and incubated with ferricytochrome c (100 µM, Sigma
Chemical) in a total volume of 900 μl PBS in the presence or absence
of varying concentrations of apocynin (MW = 166 g/mol; Sigma

Figure 1: Ischemia/reperfusion insults leads to mitochondria damage releasing O2- to initiate the oxidation process of BH4 to BH2 causing the uncoupling of eNOS.
Meanwhile cytokine mediated receptor stimulation activates protein kinase C which in turn phosphorylates NAPDH and eNOS to produce O2- that also leads to the
increase of oxidation of BH4 to BH2 causing more uncoupling of eNOS. Collectively these sources of reactive oxygen species reduce the amount of nitric oxide
available. Modified from Wilkinson et al. and Schmidt and Alp [15,38].
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Chemical), 40 µM, 400 µM, or 1 mM, respectively, for 15 min at 37°C
in spectrophotometric cells. The PMNs were stimulated with 1 μM
N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP, MW = 437
g/mol; Calbiochem) in a final reaction volume of 1.0 ml. Absorbance
at 550 nm was measured every 30 sec for up to 90 sec for fMLP (peak
response), and the change in absorbance (SO release) from PMNs was
determined relative to time 0. The dose-response curve of apocynin
on PMN SO release was used to determine a dose range that may be
effective in myocardial ischemia/reperfusion experiments.

Isolated rat heart preparation
SD rats were injected with pentobarbital sodium 60 mg/kg and
sodium heparin (1,000 U) Intra peritoneally (I.P.); after which the hearts
were rapidly excised. The plasma was collected from the abdominal
aorta of the same rat from which the heart was isolated for each cardiac
perfusion experiment in order to be used infusion at the beginning of
reperfusion [24]. The isolated rat heart was cannulated via the aorta
onto a perfusion needle and immersed in a water-jacketed reservoir
that contained 160 ml of Krebs’ buffer. The hearts were perfused with
a modified Krebs’ buffer (in mmol/l: 17.0 dextrose, 120.0 NaCl, 25.0
NaHCO3, 2.5 CaCl2, 0.5 EDTA, 5.9 KCl, and 1.2 MgCl2) maintained at
37oC at a constant pressure of 80 mmHg and aerated with 95% O2-5%
CO2 to keep the pH at 7.3-7.4. A side arm in the perfusion line proximal
to the heart inflow cannula allowed infusion of plasma (control hearts)
or plasma containing apocynin (40 µM, 400 µM and 1 mM). Coronary
flow was monitored by a flowmeter (T106, Transonic Systems, Inc.,
Ithaca, NY). Left ventricular developed pressure, which is the left
ventricular end-systolic pressure minus left ventricular end-diastolic
pressure, the maximal and minimal rate of left ventricular developed
pressure (+ dP/dtmax and – dP/dtmin, respectively) and heart rate were
monitored using a pressure transducer (SPR-524, Millar Instruments,
Inc., Houston, TX) positioned in the left ventricular cavity and
recorded using a Powerlab Station acquisition system (ADInstruments,
Grand Junction, CO). Coronary flow, left ventricular developed
pressure, + dP/dtmax, – dP/dtmin and heart rate were measured every
5 min for 15 min to obtain baseline measurements. After baseline,
global ischemia was induced for 30 min by stopping the flow of Krebs’
buffer. Hearts were infused at the beginning of reperfusion with plasma
or plasma containing apocynin at a rate of 1 ml/min for 5 min. Data
continued to be recorded every 5 min for the 45 min reperfusion. At
the end of the experiment, the infarct area and area-at-risk (i.e. entire
heart) was visualized and measured by treating the tissue with 1%
2,3,5-triphenyltetazolium (TTC), as previously described [25].

ischemia and 45 min reperfusion. The changes in H2O2 or NO release
(in pA) during ischemia/reperfusion are expressed as relative change
to baseline (initial) readings. Thereafter, the values were converted to
the concentration of H2O2 (μM) or NO (nM) after correction to the
respective calibration curves. The values recorded from the femoral
vein of the ischemia/reperfusion limb were subtracted from the values
of the sham limb to yield a net difference and were recorded every 5
min continuously on time course graphs.

Statistical analysis
All data in the text and figures are presented as means ± S.E.M.
The data were analyzed by analysis of variance using post hoc analysis
with the Student-Newman-Keuls test for PMN SO release and cardiac
function/infarct size/area-at-risk and Student’s t-test for the hindlimb
ischemia/reperfusion data. Probability values of ≤ 0.05 are considered
to be statistically significant.

Results
Apocynin dose-dependently decreased fMLP-induced PMN
SO release
PMNs release SO principally by activating NADPH oxidase. fMLP
peptide activates PMN chemotactic receptor to generate the second
messengers Ca++ and DAG that activates protein kinase C isoforms to
phosphorylate serine residues on p47phox to promote NADPH oxidase
assembly at the PMN membrane to generate SO release (Figure 1). We
found that apocynin exhibited dose-dependent reduction in fMLPstimulated PMN SO release (Figure 3). Apocynin at 40 μM had no
effect on PMN SO, whereas 400 μM and 1 mM significantly inhibited
this response by 64 ± 7 and 87 ± 7%, respectively. The data generated
from this assay was used to test a similar dose range of apocynin in the
isolated rat heart ischemia/reperfusion experiments.

Apocynin attenuated post-reperfused cardiac dysfunction
and infarct size and area-at-risk
Apocynin given at reperfusion significantly does-dependently
attenuated ischemia/reperfusion induced cardiac contractile
dysfunction and improved post-reperfused left ventricular developed
pressure to 60 ± 6% (40 µM; p < 0.05) and 74 ± 3.6% (400 μM; p < 0.01)
and 66 ± 3.6% (1 mM; p < 0.01) of baseline at 45 min post-reperfusion
compared to control ischemia/reperfusion hearts that only recovered
to 47 ± 5% of baseline values for left ventricular developed pressure
(Table 1). Apocynin (400 μM and 1 mM) significantly reduced post-

Hind limb ischemia/reperfusion in vivo procedure
We measured blood H2O2/NO release in real-time from sensors
placed in the femoral veins of male SD rats anesthetized with
sodium pentobarbital (60 mg/kg, I.P. for induction and 30 mg/kg IP
for maintenance). Thereafter, one limb was subjected to ischemia/
reperfusion, while the other limb was used as a non-ischemic sham
control in the same rat. The H2O2 or NO microsensors (100 µm, World
Precision Instruments [WPI] Inc., Sarasota, FL) were connected to a
free radical analyzer (Apollo 4000, WPI Inc.) and inserted into a 24
gauge catheter placed inside each femoral vein, as previously described
by Perkins et al. [8] and reviewed by Young et al. [26]. Ischemia in
one hind limb was induced by clamping the femoral artery/vein for
20 min followed by 45 min of reperfusion. Apocynin (13.7 mg/kg
prepared in saline; ~ 1 mM in blood) or saline (non-drug control
group) was administered at the beginning of reperfusion as a bolus via
the jugular vein. We continuously recorded and collected the H2O2 or
NO release data at 5 min intervals during a 15 min baseline, 20 min
Cardiovasc Pharm Open Access
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Figure 2: Schematic showing the inactive and active forms of NADPH
oxidase. Red-line denotes the area of inhibition performed by apocynin.
Adapted from Wilkinson et al. [38].
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Cardiac Parameters

Control I/R (n = 13)

I/R + apocynin 40 μM
(n = 9)

I/R + apocynin 400 μM
(n = 15)

I/R + apocynin 1 mM
(n = 10)

Initial LVDP (mmHg)

87 ± 3.7

92 ± 3.1

92 ± 3.1

94 ± 3.4

Final LVDP (mmHg)

41 ± 4.6

55 ± 6*

68 ± 3.4**

62 ± 3.4**

Initial LVESP (mmHg)

98 ± 3.9

105 ± 3.2

103 ± 3.5

104 ± 3.8

Final LVESP (mmHg)

101 ± 5.8

111 ± 6.4

111 ± 4

111 ± 4.6

Initial LVEDP (mmHg)

11 ± 0.6

14 ± 0.7

11 ± 0.8

10 ± 0.9

Final LVEDP(mmHg)

60 ± 5.2

56 ± 4.8

43 ± 3.8**

48 ± 4.9*

Initial + dP/dtmax (mmHg/sec)

2336 ± 73

2331 ± 56

2284 ± 69

2385 ± 101

Final + dP/dtmax (mmHg/sec)

882 ± 104

1121 ± 135

1446 ± 89**

1342 ± 95**

Initial dP/dtmin (mmHg/sec)

-1554 ± 72

-1585 ± 45

-1585 ± 68

-1617 ± 112

Final dP/dtmin (mmHg/sec)

-745 ± 57

-793 ± 99

-1091 ± 58**

-928 ± 45

Initial coronary flow (ml/min)

16.5 ± 1.3

19.1 ± .0.9

21 ± 1.3

17 ± 1.5

Final coronary flow (ml/min)

7.8 ± 0.57

10.5 ± 1.1

11.8 ± 1.4

8.9 ± 0.84

Initial Heart Rate (BPM)

279 ± 14.3

283 ± 16.5

273 ± 6.7

273 ± 11.1

Final Heart Rate (BPM)

239 ± 16.9

259 ± 13.1

245 ± 8.5

239 ± 9.6

*p < 0.05, **p < 0.01 versus control I/R final cardiac function parameters
I/R = Ischemia/Reperfusion
LVDP = Left Ventricular Developed Pressure
LVESP = Left Ventricular End-Systolic Pressure
LVEDP = Left Ventricular End-Diastolic Pressure
Table 1: Cardiac function parameters among different experimental groups.

reperfused left ventricular end-diastolic pressure compared to control
ischemia/reperfusion values by 17 ± 3.8 (p < 0.01) and 12 ± 4.9 mmHg
(p < 0.05). Whereas, apocynin 40 μM did not significantly affect this
parameter compared to ischemia/reperfusion controls (Table 1).
Similarly, apocynin exhibited a dose-dependent effect on reducing
infarct size/area-at-risk, as illustrated in Figure 4.
Other cardiac function parameters are illustrated in Table 1. Of
interest, dose-dependent effects of apocynin were also observed for
+ dP/dtmax. Specifically, apocynin improved post-reperfused + dP/dtmax
by 48 ± 6% (40 µM), 63 ± 4% (400 µM; p < 0.01), and 56 ± 4% (1
mM; p < 0.01) at 45 min reperfusion compared to control ischemia/
reperfusion hearts that only recovered to 38 ± 4%. Sham hearts (n = 6)
were not subjected to ischemia/reperfusion and maintained cardiac
function parameters and flow by > 90% and had < 5% infarct size/areaat- risk throughout the experimental time-course (data not shown).

Apocynin reduced blood H2O2 levels
Apocynin given I.V. (13.7 mg/kg) at the beginning of reperfusion
decreased H2O2 in hind limb ischemia/reperfusion models compared
to saline controls (Figure 5). Specifically, in saline control trails, H2O2
peaked up to 2.5 μM during the first 5 min of reperfusion. Thereafter,
the levels of H2O2 dropped to 1μM in blood, a concentration that was
maintained throughout the reperfusion period. By contrast, apocynintreated animals H2O2 had an increase to nearly 5 μM during the first
five minutes of reperfusion; however, the level decreased, up to 4-fold,
compared to saline control trials throughout the experimental time
course. Of note, the decreased H2O2 levels were significantly different
compared to saline controls between 20 and 45 min.

reperfusion. These levels quickly dropped to ~ 50 nM between 10
and 20 min post-reperfusion, but at 20 min post-reperfusion began
to significantly rise to ~ 130 nM throughout the remainder of the
reperfusion time period (p < 0.05 at 20 min and p < 0.01 from 25-45
min).

Discussion
Summary of findings
The major findings of this study are as follows: 1. Apocynin dosedependently attenuated fMLP-induced leukocyte SO release by 64
± 7% and 87 ± 7% at 400 μM and 1mM, compared to untreated controls
(p < 0.01); 2. In isolated perfused hearts, apocynin attenuated infarct
size/area-at-risk by 39 ± 7% (40 μM), 28 ± 4% (400 μM; p < 0.01) and
29 ± 6% (1 mMp < 0.01), compared to control ischemia/reperfusion
hearts that had an infarct size/area-at-risk of 46 ± 2%; 3. Apocynin
decreased left ventricular end-diastolic pressure to 56 ± 5% (40 μM),
43 ± 4% (400 μM; p < 0.01) and 48 ± 5% (1 mM; p < 0.05) compared

Apocynin increased blood NO levels
Apocynin given I.V. (13.7 mg/kg) at the beginning of reperfusion
increased NO in hind limb ischemia/reperfusion models compared to
saline controls (Figure 6). Blood NO levels in saline controls a brief
transiently increased to ~ 30 nM during the first 5 min of reperfusion;
however, the levels decreased to approximately 50 nM, compared
to baseline, at the end of the experimental time course. Conversely,
apocynin-treated animals’ blood NO levels significantly increased
to ~ 180 nM, as compared to baseline, during the first 5 min of
Cardiovasc Pharm Open Access
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Figure 3: fMLP (1 μM)-induced SO release in PMNs. The peak response
in SO release (90 sec). Apocynin (ApoC) (400 µM and 1 mM) significantly
attenuated fMLP-induced SO release by 64 ± 7% and 87 ± 7%, respectively,
compared to fMLP (**P < 0.01).
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reperfusion in part through activation of TNFα receptors that in
turn activate protein kinase C [20,27,28]. Activated protein kinase C
isoforms (e.g., alpha, beta II and zeta) phosphorylate serine residues
on cytosolic p47phox, which is primarily expressed in leukocytes and
vascular endothelium, to promote assembly and activation of NADPH
oxidase [27,29] leading to the production of SO (Figure 1). It has been
indicated that NADPH oxidase activation is the initial source of SO,
that in part mediates mitochondrial potassium ATP channel opening
and release of reactive oxygen species during angiotensin II induced
preconditioning [30]. It is well-known that transient mitochondrial
potassium ATP channel opening is important to induce preconditioning
in the heart to reduce infarct size [31]. However, prolonged opening
of this mitochondrial channel throughout prolonged ischemia
(i.e., 30 min) and during reperfusion does not reduce infarct size
compared to untreated I/R controls [32]. Consequently, prolonged
opening of mitochondria potassium ATP channels during ischemia
and reperfusion may contribute to oxidative stress during ischemia/
reperfusion and in turn further oxidize BH4 to BH2 to promote eNOS
uncoupling and further reactive oxygen species release (Figure 1).

Figure 4: Representative heart sections of control ischemia/reperfusion,
ischemia/reperfusion + 40 µM, 400 µM and1 mM apocynin subjected to TTC
staining. Viable tissue is stained red while the infarcted tissue remained
unstained (white). The graph shows the ratio of infarcted tissue weight to
the total tissue weight. Dose-dependent apocynin treatment significantly
decreased infarct size by 39 ± 7% (40 μM), 28 ± 4% (400 μM) and 29 ± 6% (1
mM) compared to untreated control myocardial ischemia/reperfusion hearts
(**p < 0.01).

Figure 5: The relative difference in H2O2 release between ischemia/
reperfusion and sham femoral veins during reperfusion in anesthetized rats
when given saline (n = 7) or apocynin (13.7 mg/kg; n = 6). Apocynin treated
rats showed a significant reduction in blood H2O2 release compared to salinetreated controls from 20 min to 45 min of reperfusion (*p < 0.05, **p < 0.01).

to control ischemia/reperfusion hearts that were 60 ± 5%; 4. Apocynin
significantly decreased blood H2O2 levels and increased blood NO by
four-fold compared to saline controls at the end of reperfusion (both,
p < 0.01). These results suggest that apocynin exerted cardio protective
effects by inhibiting reactive oxygen species release generated by
NADPH oxidase during ischemia/reperfusion.

The role of NADPH oxidase and oxidative stress during
ischemia/reperfusion
NADPH oxidase activity is increased in myocardial ischemia/

Cardiovasc Pharm Open Access
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Regarding NADPH oxidase and eNOS uncoupling, activation of
Protein kinase C beta II isoform is mostly responsible for NADPH
oxidase activation and inhibition of eNOS activity [23,33]. Our
previous studies found that a selective PKC beta II peptide inhibitor
significantly attenuated oxidative stress in hind limb I/R and restored
post-reperfused cardiac function in isolated I/R hearts [23,33,34].
Given that increased uncoupled eNOS activity facilities oxidative
stress, the antioxidant and cardioprotective effects of Protein kinase
C beta II inhibitor most likely are principally due to inhibition on
NADPH oxidase effects which in turn would reduce oxidation of BH4
to BH2 and therefore attenuate uncoupled eNOS activity. Therefore,
understanding vascular/cardiac NADPH oxidase during reperfusion
following prolonged ischemia may disclose the triggering source of
oxidative stress in reperfusion injury (Figure 1). Our in vivo and ex vivo
hind limb and myocardial ischemia/reperfusion models will largely
exclude the contribution of polymorphonuclear leukocyte NADPH
oxidase because they are recruited into the reperfusion site after a few
hours of reperfusion.
Apocynin is a selective NADPH oxidase inhibitor that works
by blocking the association of p47phox with the membrane p22phox
in endothelial cells and leukocytes [14,35] (Figure 1). Apocynin
is considered to be a prodrug that is converted to diapocynin by
endothelial peroxidase and leukocyte myeloperoxidase which then
oxidizes cysteine-196 on p47phox and thereby inhibits NADPH oxidase
assembly and activation [22]. P47phox is highly expressed in myeloid and
vascular smooth muscle/endothelial cells [10]. Therefore, the primary
target for apocynin would be attenuation of vascular NADPH oxidase
during ischemia and early reperfusion since only resident PMNs would
be present during this time. Mozaffari et al. [13] reported that apocynin
(100 μM) given during pre-ischemia improved + dP/dtmax and + dP/
dtmin and decreased infarct size/area-at-risk compared to untreated
controls in isolated perfused rat hearts subjected to 40 min regional
ischemia followed by 2 hour reperfusion [13]. However, their study
did not measure SO or H2O2 release in the post-reperfused tissue
to assess the level of reactive oxygen species attenuation induced by
apocynin to attribute a mechanism of action. Moreover, they did not
give apocynin exclusively during reperfusion since pretreatment is not
always a clinical option. Therefore, it is of high clinical importance
to determine the degree of reactive oxygen species inhibition from
NADPH oxidase and its relative contribution during the reperfusion
phase of ischemia/reperfusion injury. Another study by Jiao et al. [36],
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blood flow contacting the respective microsensor [4,7,8]. Subsequent
measurements after this initial burst may more accurately represent the
relative increase or decrease of the biomolecule being measured (i.e.,
H2O2 or NO).

Conclusion

Figure 6: The relative difference in NO release between ischemia/
reperfusion and sham femoral veins during reperfusion in anesthetized rats
when given saline (n = 7) or apocynin (13.7 mg/kg; n = 6). Apocynin treated
rats showed a significant increase in blood NO release compared to salinetreated controls from 20 min to 45 min of reperfusion (*p < 0.05, **p < 0.01).

reported that apocynin reduced SO in cardiac ischemia/reperfusion
tissue, which was associated with a decrease in infarct size/area-atrisk compared to controls in mice subjected to regional ischemia for
30 min followed by 24 hour reperfusion and administered apocynin
I.V. (5 mg/kg) 10 min prior to reperfusion. However, their study did
not assess cardiac function or infarct size/area-at-risk, which may be
associated with the decreased SO release [36]. Similarly, another study
by Gao et al. [28] also performed regional ischemia in mice for 30 min
followed by 90 min reperfusion and found that acetylcholine (Ach)induced vasodilatation in isolated coronary arterioles was improved in
mice given apocynin I.V. (25 mg/kg) prior to reperfusion. This effect
was associated with decreased SO production [28]. Moreover, their
study attributed the increased NADPH oxidase activity to increased
TNFα released from vascular smooth muscle in myocardial ischemia/
reperfusion tissue. However, like the Jiao et al. study, Gao et al. study
did not assess cardiac function or infarct size/area-at-risk.
Interestingly, apocynin at 1 mM did not improve cardiac function,
infarct size or area-at-risk compared to the 400 μM dose. It is possible
that apocynin exerted its maximal effect at 400 μM in the isolated
perfused heart study. In contrast, the SO release from leukocytes was
inhibited to a greater extent at 1 mM compared to 400 μM, suggesting
that vascular and cardiac myocyte NADPH oxidase may have reached
its maximal inhibition at 400 μM. It is also possible that the 1 mM dose
may have started to exert some paradoxical oxidative stress in the heart
tissue.
According to Riganti et. al. [37], apocynin induced oxidative stress
in a dose-dependent way in glial cells in vitro. Furthermore, high
concentration apocynin incubated in cultured glial cells showed an
increase in oxidative stress via measurements of lipid peroxidation,
H2O2, and cytotoxic level. It should be emphasized that the
concentration of apocynin used in the hindlimb ischemia/reperfusion
model (i.e., 13.7 mg/kg) approximated to a concentration of about
1 mM in blood. However, given that apocynin is a small molecular
compound that could be cleared by the kidneys, it is plausible that the
effective dose was less in the blood over time since it took about 20
minutes for apocynin to exert significant effects on blood H2O2 levels
and NO levels. Of interest, it should be noted that the initial increase
in blood H2O2 and NO levels observed in both saline and apocynintreated animals is consistent with previous studies showing an initial
increase in these levels, and may, in part, be due to the initiation of
Cardiovasc Pharm Open Access
ISSN: 2329-6607 CPO, an open access journal

In summary, apocynin exerted cardio protective effects on postrefused cardiac function that paralleled a decrease in infarct size/areaat-risk. Moreover, the reduction of blood H2O2 release and increased
NO bioavailability in the hind limb ischemia/reperfusion model
suggests that apocynin exerted its cardio protective effects via the
inhibition of SO release. Collectively, this study suggests that NADPH
oxidase significantly contributes to reactive oxygen species production
during ischemia/reperfusion and that inhibiting this production during
reperfusion in effective to attenuate oxidative stress and subsequent
cardiac cell death and cardiac contractile dysfunction. However, it is
possible that the results of apocynin may in part be due to scavenging
H2O2 in addition to selective inhibition of NADPH oxidase as suggested
by Johnson et al. [35].

Funding Sources
Center for Chronic Diseases of Aging at P.C.O.M.
Acknowledgement
Stephanie Liu, Graduate Student at P.C.O.M., for assisting with editing of this
manuscript.

References
1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, et al. (2011) Heart
disease and stroke statistics-2011 update: a report from the American Heart
Association. Circulation 123: e18-e209.
2. Hausenloy DJ, Yellon DM (2013) Myocardial ischemia-reperfusion injury: a
neglected therapeutic target. J Clin Invest 123: 92-100.
3. Lefer AM, Lefer DJ (1996) The role of nitric oxide and cell adhesion molecules
on the microcirculation in ischaemia-reperfusion. Cardiovasc Res 32: 743-751.
4. Chen Q, Kim EE, Elio K, Zambrano C, Krass S, et al. (2010) The role of
tetrahydrobiopterin and dihydrobiopterin in ischemia/reperfusion injury when
given at reperfusion. Adv Pharmacol Sci 2010: 963914.
5. Tsao PS, Aoki N, Lefer DJ, Johnson G , Lefer AM (1990) Time course of
endothelial dysfunction and myocardial injury during myocardial ischemia and
reperfusion in the cat. Circulation 82: 1402-1412.
6. Hayward R, Lefer AM (1998) Time course of endothelial-neutrophil interaction
in splanchnic artery ischemia-reperfusion. Am J Physiol 275: H2080-2086.
7. Teng JC, Kay H, Chen Q, Adams JS, Grilli C, et al. (2008) Mechanisms related
to the cardioprotective effects of protein kinase C epsilon (PKC epsilon) peptide
activator or inhibitor in rat ischemia/reperfusion injury. Naunyn Schmiedebergs
Arch Pharmacol 378: 1-15.
8. Perkins KA, Pershad S, Chen Q, McGraw S, Adams JS, et al. (2012) The
effects of modulating eNOS activity and coupling in ischemia/reperfusion (I/R).
Naunyn Schmiedebergs Arch Pharmacol 385: 27-38.
9. Schramm A, Matusik P, Osmenda G, Guzik TJ (2012) Targeting NADPH
oxidases in vascular pharmacology. Vascul Pharmacol 56: 216-231.
10. Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH
oxidases: physiology and pathophysiology. Physiol Rev 87: 245-313.
11. Ago T, Kuroda J, Kamouchi M, Sadoshima J, Kitazono T (2011)
Pathophysiological roles of NADPH oxidase/nox family proteins in the vascular
system. Review and perspective. Circ J 75: 1791-1800.
12. Doughan AK, Harrison DG, Dikalov SI (2008) Molecular mechanisms of
angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial
oxidative damage and vascular endothelial dysfunction. Circ Res 102: 488-496.
13. Mozaffari MS, Baban B, Liu JY, Abebe W, Sullivan JC, et al. (2011) Mitochondrial
complex I and NAD(P)H oxidase are major sources of exacerbated oxidative
stress in pressure-overloaded ischemic-reperfused hearts. Basic Res Cardiol
106: 287-297.

Volume 5 • Issue 2 • 1000176

Citation: Chen Q, Parker WC, Devine I, Ondrasik R, Habtamu T, et al. (2016) Apocynin Exerts Dose-Dependent Cardioprotective Effects by
Attenuating Reactive Oxygen Species in Ischemia/Reperfusion. Cardiovasc Pharm Open Access 5: 176. doi:10.4176/2329-6607.1000176

Page 7 of 7
14. Kleniewska P, Piechota A, Skibska B, Gorąca A (2012) The NADPH oxidase
family and its inhibitors. Arch Immunol Ther Exp (Warsz) 60: 277-294.

C inhibitor that attenuates myocardial ischemia/reperfusion injury. Cardiovasc
Drug Rev 23: 255-272.

15. Schmidt TS, Alp NJ (2007) Mechanisms for the role of tetrahydrobiopterin in
endothelial function and vascular disease. Clin Sci (Lond) 113: 47-63.

28. Gao Y, Fang X, Tong Y, Liu Y, Zhang B (2009) TLR4-mediated MyD88dependent signaling pathway is activated by cerebral ischemia-reperfusion in
cortex in mice. Biomed Pharmacother 63: 442-450.

16. Vasquez-Vivar J, Martásek P, Whitsett J, Joseph J, Kalyanaraman B (2002)
The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin
analogues controls superoxide release from endothelial nitric oxide synthase:
an EPR spin trapping study. Biochem J 362: 733-739.
17. Duda M, Konior A, Klemenska E, Beresewicz A (2007) Preconditioning protects
endothelium by preventing ET-1-induced activation of NADPH oxidase and
xanthine oxidase in post-ischemic heart. J Mol Cell Cardiol 42: 400-410.
18. Fabian RH, Perez-Polo JR, Kent TA (2008) Perivascular nitric oxide and
superoxide in neonatal cerebral hypoxia-ischemia. Am J Physiol Heart Circ
Physiol 295: H1809-1814.
19. Nolly MB, Caldiz CI, Yeves AM, Villa-Abrille MC, Morgan PE, et al. (2014)
The signaling pathway for aldosterone-induced mitochondrial production of
superoxide anion in the myocardium. J Mol Cell Cardiol 67: 60-68.
20. Frangogiannis NG, Perrard JL, Mendoza LH, Burns AR, Lindsey ML, et al.
(1998) Stem cell factor induction is associated with mast cell accumulation after
canine myocardial ischemia and reperfusion. Circulation 98: 687-698.
21. Stefanski J and Pawliczak R (2008) Apocynin: Molecular Aptitudes. Mediators
of Inflammation 1-10.
22. Mora-Pale M, Kwon SJ, Linhardt RJ, Dordick JS (2012) Trimer hydroxylated
quinine derived from apocynin targets cysteine residues of p47phox preventing
the activation of human vascular NADPH oxidase.” Free Radic Biol Med 52:
962-969.
23. Omiyi D, Brue RJ, Taormina P 2nd, Harvey M, Atkinson N, et al. (2005) Protein
kinase C betaII peptide inhibitor exerts cardioprotective effects in rat cardiac
ischemia/reperfusion injury. J Pharmacol Exp Ther 314: 542-551.
24. Peterman EE, Taormina P 2nd, Harvey M, Young LH (2004) Gö 6983 exerts
cardioprotective effects in myocardial ischemia/reperfusion. J Cardiovasc
Pharmacol 43: 645-656.
25. Blakeman N, Qian Chen, Jasmine Tolson, Brian Rueter, Brian Diaz, et al. (2012)
Triacsin C, a fatty acyl coA synthetase inhibitor, improves cardiac performance
following global ischemia. American Journal of Biomedical Sciences 4: 249261.
26. Young LH, Qian Chen, Margaret T Weis (2011) Direct Measurement of
Hydrogen Peroxide (H2O2) or Nitric Oxide (NO) Release: A Powerful Tool to
Assess Real-time Free Radical Production in Biological Models. Am J BioMed
Sci 3: 40-49.

29. Yu J, Weïwer M, Linhardt RJ, Dordick JS (2008) The role of the methoxyphenol
apocynin, a vascular NADPH oxidase inhibitor, as a chemopreventative agent
in the potential treatment of cardiovascular diseases. Curr Vasc Pharmacol 6:
204-217.
30. Raval AP, Dave KR, DeFazio RA, Perez-Pinzon MA (2007) epsilonPKC
phosphorylates the mitochondrial K(+) (ATP) channel during induction of
ischemic preconditioning in the rat hippocampus. Brain Res 1184: 345-353.
31. Garlid KD, Dos Santos P, Xie ZJ, Costa AD, Paucek P (2003) Mitochondrial
potassium transport: the role of the mitochondrial ATP-sensitive K(+) channel in
cardiac function and cardioprotection. Biochim Biophys Acta 1606: 1-21.
32. Pomerantz BJ, Thomas N Robinson, Julie K Heimbach, Casey M Calkins,
Stephanie A Miller, et al. (2000) Selective mitochondrial KATP channel opening
controls human myocardial preconditioning: too much of a good thing? Surgery
128: 368-373.
33. Korchak HM, Kilpatrick LE (2001) Roles for beta II-protein kinase C and
RACK1 in positive and negative signaling for superoxide anion generation in
differentiated HL60 cells. J Biol Chem 276: 8910-8917.
34. Chen Q, Brian Rueter, Samuel Krass, Christopher Zambrano, Shawn Thomas,
et al. (2010) The potential clinical application of protein kinase C beta II
peptide inhibitor and Gö 6983 in vascular endothelial dysfunction. Curr Topics
Pharmacol 14: 11-24.
35. Johnson DK, Schillinger KJ, Kwait DM, Hughes CV, McNamara EJ, et al.
(2002) Inhibition of NADPH oxidase activation in endothelial cells by orthomethoxy-substituted catechols. Endothelium 9: 191-203.
36. Jiao XY, Gao E, Yuan Y, Wang Y, Lau WB, et al. (2009) INO-4885
[5,10,15,20-tetra[N-(benzyl-4’-carboxylate)-2-pyridinium]-21H,23H-porphine
iron(III) chloride], a peroxynitrite decomposition catalyst, protects the heart
against reperfusion injury in mice. J Pharmacol Exp Ther 328: 777-784.
37. Riganti C, Costamagna C, Bosia A, Ghigo D (2006) The NADPH oxidase
inhibitor apocynin (acetovanillone) induces oxidative stress. Toxicol Appl
Pharmacol 212: 179-187.
38. Wilkinson BL, Landreth GE (2006) The microglial NADPH oxidase complex as
a source of oxidative stress in Alzheimer’s disease. J Neuroinflammation 3: 30.

27. Young LH, Balin BJ, Weis MT (2005) Gö 6983: a fast acting protein kinase

OMICS International: Publication Benefits & Features
Unique features:
•
•
•

Increased global visibility of articles through worldwide distribution and indexing
Showcasing recent research output in a timely and updated manner
Special issues on the current trends of scientific research

Special features:

Citation: Chen Q, Parker WC, Devine I, Ondrasik R, Habtamu T, et al. (2016)
Apocynin Exerts Dose-Dependent Cardioprotective Effects by Attenuating
Reactive Oxygen Species in Ischemia/Reperfusion. Cardiovasc Pharm Open
Access 5: 176. doi:10.4176/2329-6607.1000176

Cardiovasc Pharm Open Access
ISSN: 2329-6607 CPO, an open access journal

•
•
•
•
•
•
•
•

700 Open Access Journals
50,000 editorial team
Rapid review process
Quality and quick editorial, review and publication processing
Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus, Google Scholar etc.
Sharing Option: Social Networking Enabled
Authors, Reviewers and Editors rewarded with online Scientific Credits
Better discount for your subsequent articles

Submit your manuscript at: http://www.omicsonline.org/submission

Volume 5 • Issue 2 • 1000176

